Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Up 8.2% – Here’s What Happened

Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) rose 8.2% during trading on Monday . The stock traded as high as $14.04 and last traded at $13.8360. Approximately 437,609 shares changed hands during mid-day trading, a decline of 78% from the average daily volume of 2,033,126 shares. The stock had previously closed at $12.79.

Analyst Ratings Changes

ADPT has been the subject of several analyst reports. Wall Street Zen downgraded shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Piper Sandler set a $21.00 target price on shares of Adaptive Biotechnologies in a report on Friday, February 6th. JPMorgan Chase & Co. increased their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Friday, February 6th. Guggenheim increased their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a report on Monday, January 26th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Adaptive Biotechnologies has a consensus rating of “Moderate Buy” and a consensus target price of $18.25.

Adaptive Biotechnologies Price Performance

The business’s fifty day moving average is $14.79 and its 200-day moving average is $16.00. The firm has a market cap of $2.24 billion, a PE ratio of -36.32 and a beta of 2.29.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The business had revenue of $71.68 million during the quarter, compared to the consensus estimate of $59.38 million. During the same quarter last year, the company posted ($0.23) earnings per share. The firm’s quarterly revenue was up 51.0% compared to the same quarter last year. Analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Insider Activity at Adaptive Biotechnologies

In related news, insider Francis Lo sold 22,564 shares of the firm’s stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $15.07, for a total transaction of $340,039.48. Following the completion of the sale, the insider owned 271,154 shares in the company, valued at approximately $4,086,290.78. This trade represents a 7.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Julie Rubinstein sold 19,060 shares of the firm’s stock in a transaction dated Monday, April 13th. The stock was sold at an average price of $13.15, for a total transaction of $250,639.00. Following the sale, the chief operating officer owned 421,174 shares of the company’s stock, valued at $5,538,438.10. This trade represents a 4.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 2,460,881 shares of company stock worth $35,488,040. 6.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Adaptive Biotechnologies

A number of large investors have recently added to or reduced their stakes in ADPT. Allianz Asset Management GmbH boosted its position in Adaptive Biotechnologies by 305.8% during the third quarter. Allianz Asset Management GmbH now owns 321,774 shares of the company’s stock worth $4,814,000 after purchasing an additional 242,474 shares during the period. SG Americas Securities LLC boosted its position in Adaptive Biotechnologies by 82.5% during the third quarter. SG Americas Securities LLC now owns 68,113 shares of the company’s stock worth $1,019,000 after purchasing an additional 30,785 shares during the period. Affinity Wealth Management LLC bought a new position in Adaptive Biotechnologies during the third quarter worth about $4,541,000. Aristotle Atlantic Partners LLC boosted its position in Adaptive Biotechnologies by 8.6% during the third quarter. Aristotle Atlantic Partners LLC now owns 3,126,719 shares of the company’s stock worth $46,776,000 after purchasing an additional 247,402 shares during the period. Finally, Huntleigh Advisors Inc. bought a new position in Adaptive Biotechnologies during the third quarter worth about $1,227,000. Hedge funds and other institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.